DDInter1901 DDInter1658
Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by synovial inflammation and hyperplasia, autoantibody production, cartilage damage and bone destruction, leading to co-morbidities. Despite a variety of therapeutic agents available for treatment, up to 40% of the patients do not respond to current therapies, including biological therapies. The etiology of the disease is mostly unknown; however, the role of JAK as a driver of immune-mediated conditions was discovered, leading to the use of JAK as therapeutic targets for rheumatoid arthritis. To reduce dose-related toxicity (as seen with some pan-JAK inhibitors) without significantly affecting efficacy, more selective JAK1 inhibitors, upadac
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Upadacitinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc gluconate
Upadacitinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sipuleucel-T
Upadacitinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Somapacitan
Upadacitinib {u} may lead to a major life threatening interaction when taken with {v} Anakinra
Upadacitinib {u} may lead to a major life threatening interaction when taken with {v} Lisocabtagene maraleucel
Upadacitinib may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate
Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T
Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Upadacitinib may lead to a major life threatening interaction when taken with Anakinra
Upadacitinib may lead to a major life threatening interaction when taken with Lisocabtagene maraleucel